Investigation of the Analgesic Properties L-759,633 and SER 601 in Experimental Neuropathic Pain Model in Rats and their Comparison with Pregabalin
Abstract
Despite the fact that narcotics and NSAIDs are the mainstays of nociceptive pain care, only a small proportion of neuropathic pain patients benefit from them. Cannabinoid agents could be a viable alternative to opioids in the management of chronic pain. The goal of our investigation was to assess the analgesic efficacy of SER 601 and L-759,633, cannabinoid receptor 2 (CB2) agonists, at various doses in a model of neuropathic pain generated in rat. The analgesic effect of CB2 agonists L-759,633 and SER 601 at various doses in a rat model of neuropathic pain created by partial sciatic nerve ligation was examined by the hot plate method. Furthermore, a comparison of analgesic effects of both drugs with pregabalin is also conducted. The two substances demonstrated a dose-dependent analgesic effect in this model. The analgesic response of SER601 and L-759,633 in the neuropathic pain model was higher compared to that of pregabalin. All in all, our data suggest that SER601 and L-759,633 may offer a beneficial treatment option for neuropathic pain in future.
Keywords
Neuropathic pain, L-759, 633, SER 601, Hot plate, Pregabalin.
Supporting Institution
cumhuriyet university scientific research project
Project Number
T-848
References
- [1] Mills S. E., Nicolson K. P., Smith B. H., Chronic pain: a review of its epidemiology and associated factors in population-based studies, British Journal of Anaesthesia, 123(2) (2019) 273-283.
- [2] Ricci L., Luigetti M., Florio L., Capone F., Di Lazzaro V., Causes of chronic neuropathies: a single-center experience, Neurological Sciences, 40(8) (2019) 611-1617.
- [3] Koetsier E., Franken G., Debets J., Heijmans L., van Kuijk S. M., Linderoth B., Maino P., Mechanism of dorsal root ganglion stimulation for pain relief in painful diabetic polyneuropathy is not dependent on GABA release in the dorsal horn of the spinal cord, CNS Neuroscience & Therapeutics, 26(1) (2020) 136-143.
- [4] Devor M., Neuropathic pain and injured nerve: Peripheral mechanisms, Br. Med. Bull., 47 (1991) 619–30.
- [5] Cohen S.P., Mao J., Neuropathic pain: Mechanisms and their clinical implications, BMJ, 348 2014.
- [6] Henningsen P., Zipfel S., Herzog W., Management of functional somatic syndromes, Lancet, 369 (2007) 946–55.
- [7] Dworkin R.H., O’Connor A.B., Backonja M., Farrar J.T., Finnerup N.B., Jensen T.S., Pharmacologic management of neuropathic pain: Evidence-based recommendations, Pain, 132 (2007) 237–51.
- [8] Lötsch J., Weyer-Menkhoff I., Tegeder I., Current evidence of cannabinoid-based analgesia obtained in preclinical and human experimental settings, Eur. J. Pain, 22 (2018) 471–84.
- [9] Ibrahim M.M., Deng H., Zvonok A., Cockayne D.A., Kwan J., Mata H.P., Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: Pain inhibition by receptors not present in the CNS, Proc. Natl. Acad. Sci., 100 (2003) 10529–33.
- [10] Meymandi M. S., Sepehri G., Abdolsamadi M., Shaabani M., Heravi G., Yazdanpanah O., Aghtaei M. M., The effects of co-administration of pregabalin and vitamin E on neuropathic pain induced by partial sciatic nerve ligation in male rats, Inflammopharmacology, 25(2) (2017) 237-246.